Clinical and disease characteristics from REVEAL at time of enrollment (baseline): Prospective observational study of patients with polycythemia vera in the United States by Grunwald, Michael R et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2018
Clinical and disease characteristics from REVEAL
at time of enrollment (baseline): Prospective
observational study of patients with polycythemia
vera in the United States
Michael R. Grunwald
Levine Cancer Institute, Atrium Health
Brady L. Stein
Northwestern University
Ralph V. Boccia
The Center for Cancer and Blood Disorders
Stephen T. Oh
Washington University School of Medicine in St. Louis
Dilan Paranagama
Incyte Corporation
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Grunwald, Michael R.; Stein, Brady L.; Boccia, Ralph V.; Oh, Stephen T.; Paranagama, Dilan; Parasuraman, Shreekant; Colucci,
Philomena; and Mesa, Ruben, ,"Clinical and disease characteristics from REVEAL at time of enrollment (baseline): Prospective
observational study of patients with polycythemia vera in the United States." Clinical Lymphoma Myeloma and Leukemia.18,12.
788-795.e2. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7414
Authors
Michael R. Grunwald, Brady L. Stein, Ralph V. Boccia, Stephen T. Oh, Dilan Paranagama, Shreekant
Parasuraman, Philomena Colucci, and Ruben Mesa
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/7414
Original Study
Clinical and Disease Characteristics From
REVEAL at Time of Enrollment (Baseline):
Prospective Observational Study of Patients With
Polycythemia Vera in the United States
Michael R. Grunwald,1 Brady L. Stein,2 Ralph V. Boccia,3 Stephen T. Oh,4
Dilan Paranagama,5 Shreekant Parasuraman,5 Philomena Colucci,5 Ruben Mesa6
Abstract
REVEAL is the ﬁrst large, prospective observational study aimed at examining the contemporary
demographics, burden of disease, clinical management, patient-reported outcomes, and health care resource
utilization in patients with polycythemia vera in the United States.
Background: Polycythemia vera (PV) has a prevalence of 44 to 57 per 100,000 people in the United States.
Prospective data concerning the demographics, clinical characteristics, and treatment patterns of patients with PV in
the United States are lacking. Patients and Methods: The ongoing, prospective, observational REVEAL study
evaluates demographics, disease burden, clinical management, patient-reported outcomes, and health care resource
utilization of adult patients with PV in the United States. This report summarizes the demographics and clinical
characteristics of patients at enrollment (baseline). Results: Patients (n ¼ 2510) were a median age of 67.0 years,
54.2% were male, and 89.1% were white. The median time from PV diagnosis to study enrollment was 4.0 (range,
0-56.3) years. Most patients (89.7%) were diagnosed after an abnormal blood test. Less than half (49.2%) underwent
JAK2 mutation analysis, of whom 95.8% were JAK2 V617F mutation positive; < 1% were positive for JAK2 exon 12
mutations. At enrollment, 47.7% of patients had elevated hematocrit (> 45%), 35.8% had elevated platelets (> 400 
109/L), and 37.0% had elevated leukocytes (> 10  109/L). Most patients (94.5%) were receiving active PV treatment,
predominantly therapeutic phlebotomy alone (33.6%), hydroxyurea monotherapy (29.0%), or hydroxyurea plus
phlebotomy (23.7%). Thrombotic events occurred in 11.9% of patients before PV diagnosis (venous, 6.7%; arterial,
5.7%), and 8.3% between diagnosis and enrollment. Hypertension (70.6%) was the most common previous medical
condition. Conclusion: REVEAL enrollment data inform our understanding of the baseline demographics, diagnostic
approach, disease characteristics, and treatment patterns of patients with PV in the United States. Longitudinal real-
world data collected in this study will complement information collected during randomized controlled clinical trials.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 12, 788-95 ª 2018 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm in
which clonal proliferation of a hematopoietic progenitor cell results
in erythrocytosis, leukocytosis, and thrombocytosis.1 With respect
to the epidemiology of PV in the United States, analyses of
administrative claims from 2008 to 2010 reported a prevalence of
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approximately 44 to 57 per 100,000 people.2 Most patients with
PV have a Janus kinase 2 (JAK2) mutation that results in consti-
tutive activation of hematopoietic signal transduction, thus
explaining the exaggerated hematopoiesis. More than 95% of pa-
tients with PV carry the JAK2 V617F mutation; w4% have mu-
tations in JAK2 exon 12.3-7
Patients with PV have an increased mortality risk relative to the
general population, primarily due to thrombotic events, trans-
formation to leukemia or myeloﬁbrosis, and solid tumors.8-12 Pa-
tients also experience a broad range of symptoms that may lead to
decreased quality of life and productivity.13-16
Large multicenter observational studies of PV have focused
primarily on European patients,13,14,16-21 whereas US studies have
been limited to single-center settings.22,23 Patterns of care can be
characterized with administrative claims databases and electronic
medical record audits. However, these data sources frequently lack
important clinical information and do not capture patient-reported
outcomes (PROs).
The ProspectiveObservational Study of PatientsWith Polycythemia
Vera in US Clinical Practices (REVEAL; ClinicalTrials.gov,
NCT02252159) was designed to collect contemporary demographics
and data on the burden of disease, clinical management, PROs, and
health care resource utilization of US patients with PV being seen at
community and academic medical centers. This report describes the
demographics as well as the clinical and disease characteristics of pa-
tients in the REVEAL study at the time of study enrollment.
Patients and Methods
Study Design
REVEAL is a multicenter, noninterventional, prospective obser-
vational study of patients with PV conducted in accordance with the
Declaration of Helsinki. Approval of all study materials by central
(Sterling IRB; Atlanta, GA) and local institutional review boards
and provision of informed consent by all patients was required,
including a separate informed consent form documenting willing-
ness to participate in an optional biological substudy to examine the
molecular features of PV. Patients with a clinical diagnosis of PV
were enrolled from community practices and academic centers in
the United States over a 24-month enrollment period. Physician
assessments and PRO outcomes (previously published24) were
recorded during routine care visits (approximately every 6 months).
Blood samples were collected at enrollment and annually for pa-
tients agreeing to participate in an optional molecular substudy. All
treatment decisions during the study were made by patients’ treating
physicians.
Eligibility Requirements
At enrollment, patients were  18 years old; had a clinical
diagnosis of PV per physician judgment; were willing and able to
provide informed consent and complete patient assessments and
questionnaires, either alone or with minimal assistance from a
caregiver or trained site personnel; and were currently under
physician supervision for management of PV. Patients were
excluded if they were participating in an active, blinded clinical trial;
had a life expectancy < 6 months; had a diagnosis of myeloﬁbrosis,
acute myeloid leukemia, or myelodysplastic syndrome; had a history
of or active plan (within 3 months of enrollment) to proceed to
allogeneic hematopoietic stem-cell transplantation; or had under-
gone splenectomy.
Assessments
This analysis describes patient demographics as well as clinical
and disease characteristics at time of diagnosis and around the time
of enrollment. Historic data pertaining to the evaluations and dis-
ease characteristics at time of diagnosis and physician-reported data
from usual care visits, including information from the 6 months
before enrollment, were collected and abstracted from electronic
medical records into an electronic data capture system. For the
purpose of this analysis, physician-reported data in the following
categories were examined: demographics and PV disease character-
istics; education, employment, insurance, and residency character-
istics; laboratory tests and procedures used to determine a diagnosis
of PV; signs and symptoms at time of PV diagnosis; laboratory
values at time of enrollment; PV-directed therapy; comorbid con-
ditions; thrombotic event history; concomitant medications; and
health care resource utilization.
The Charlson Comorbidity Index (CCI) was used to assess
morbidity.25 The CCI uses a 6-point scale to rate diagnosis codes
from the International Classiﬁcation of Diseases for each comor-
bid condition, which are summed to generate a total index score
for each patient; higher scores correspond with more severe
morbidity.
Statistical Analysis
Descriptive statistics were used. Missing data were not imputed;
however, missing dates for temporal end points were imputed when
applicable. If the entire date (ie, day, month, and year) was missing,
all corresponding data were excluded from analyses involving dates.
If the day was missing but the month and year were available, the
date was imputed as the ﬁrst day of the month. If the day and
month were missing but the year was available, the date was
imputed as January 1.
Results
Patient Demographics and PV Disease Characteristics
In this ongoing study, 2510 patients were enrolled from July 22,
2014, to August 3, 2016, from 227 US sites (39 academic and
188 community [self-identiﬁed]; Figure 1). Patients had a mean
(SD) age of 66.3 (12.3) years (Table 1), and 2.9% were young
(aged < 40 years). Most patients were male (54.2%) and white
(89.1%), and 48.1% had a history of smoking; 11.1% were active
smokers at time of enrollment. Family history of PV was docu-
mented in 132 patients (5.3%).
Median (range) disease duration was 4.0 (0-56.3) years
(Figure 2), 77.3% of patients were classiﬁed as having high-risk
disease (aged  60 years and/or history of thrombotic events),
and 72.6% were obese or overweight. Spleen assessment by physical
examination was performed in 1601 patients (63.8%) at time of
enrollment. Of these patients, 282 (17.6%) had palpable spleno-
megaly. Spleen length measurements were available for 122 patients,
51.6% of whom had spleen length  5 cm from the left costal
margin to the point of greatest splenic extension.
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Patient Education, Employment, Insurance, and
Residency Characteristics
Most patients (62.7%) had at least some college education,
33.5% were employed full time or part time, 51.1% were retired,
and 4.4% were disabled or unable to work (Supplemental Table 1).
The vast majority of patients (99.1%) had health insurance (public
only, 47.8%; private only, 40.4%; both public and private, 10.9%).
Most patients (94.9%) were living independently at home, 3.7%
were living as a dependent at home, and 0.8% were living in assisted
housing; 0.1% and 0.4% were living in long-term care facilities or
other residency settings, respectively.
PV Diagnosis
The majority of patients were reported to have abnormal he-
moglobin (59.0%) or hematocrit (57.5%) results at time of diag-
nosis (Table 2). An abnormal platelet count or erythropoietin level
was reported in only 28.7% and 20.1% of patients at time of
diagnosis, respectively. In almost half (49.2%) of patients, JAK2
mutational testing results were reported; most of these patients were
positive for JAK2 V617F (95.8%), with only 0.8% positive for
JAK2 exon 12 mutations. A JAK2 test was reported for 19.9% of
patients diagnosed before January 1, 2006, compared to 54.3% of
patients diagnosed after January 1, 2006. Bone marrow biopsy/
aspiration results were reported in 24.4% of patients. Palpable
splenomegaly was reported as a factor in the diagnosis of 7.0% of
patients. With respect to PV-speciﬁc symptoms, the most
commonly reported symptoms noted at diagnosis were tiredness
(22.0%), itching (13.9%), muscle aches and/or bone pain (8.8%),
and difﬁculty sleeping (7.8%; Table 2).
Laboratory Values
At time of enrollment, 5.3% of patients had an elevated hemo-
globin level (> 18.5 g/dL in men or > 16.5 g/dL in women),
47.7% had elevated hematocrit (> 45%), 35.8% had elevated
platelets (> 400  109/L), and 37.0% had elevated leukocytes
(> 10  109/L). Mean hemoglobin, hematocrit, platelet, and
leukocyte values at enrollment were 14.5 g/dL, 45%, 367.5 
109/L, and 10.4  109/L, respectively (Table 3).
PV-Directed Therapy at Time of Enrollment
At time of enrollment, the majority (54.6%) of patients with low-
risk disease were being managed with therapeutic phlebotomy.
However, 18.1% and 15.8% of low-risk patients were being
managed with hydroxyurea alone and phlebotomy plus hydroxy-
urea, respectively. Only 4.9% of patients with low-risk PV were
managed with watchful waiting. In contrast, hydroxyurea alone
(32.2%) and phlebotomy alone (27.4%) were the most commonly
reported PV-directed therapies in patients with high-risk PV.
Management with watchful waiting was reported for 5.7% of pa-
tients with high-risk disease (Figure 3). The most common
Figure 1 IRB-Approved Study Sites Participating in REVEAL. A Total of 2510 Patients Were Enrolled From 227 Sites Across the United
States (39 Academic and 188 Community [Self-identiﬁed])
Abbreviations: IRB ¼ institutional review board; REVEAL ¼ Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices.
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hydroxyurea daily doses were 500 mg (35.4%) and 1000 mg
(30.2%). The mean hydroxyurea daily doses were 769.5 and 834.9
mg for patients undergoing and not undergoing phlebotomy,
respectively. Among patients who were treated with therapeutic
phlebotomy, mean number of phlebotomies was 2.5 (median, 2)
during the 6 months before enrollment. A small proportion of
patients were treated with other agents (8.2%), including ruxolitinib
(3.8%), anagrelide (2.0%), and interferon (1.4%).
Comorbid Conditions
The most common comorbid conditions were hypertension
(70.6%), hyperlipidemia (30.4%), obesity (17.5%), and diabetes
mellitus (15.7%). Mean (SD) CCI was 3.4 (0.83). A history of skin
cancer (not otherwise speciﬁed) and nonmelanoma skin cancer was
documented in 3.5% and 3.3% of patients, respectively. Malignant
melanoma was noted in 1.1% of patients. A history of other
malignancies included prostate (2.9%), breast (1.9%), and colon
(1.0%) cancers (Supplemental Table 2).
History of Thrombosis
At time of study enrollment, for patients with a known PV
diagnosis date (n ¼ 2485), 468 patients (18.8%) had a documented
thrombotic event (Table 4), and 4.6% had at least 2 thrombotic
events. Venous thrombotic events had occurred in 279 patients
(11.2%); the most common were deep vein thrombosis (6.1%) and
pulmonary embolism (2.6%). Arterial thrombotic events had
occurred in 218 patients (8.8%); the most common were cerebro-
vascular arterial thrombosis (5.1%) and acute myocardial infarction
(1.8%). A total of 29 patients (1.2%) experienced both a venous
and arterial thrombotic event. Before PV diagnosis, 296 patients
(11.9%) experienced thrombotic events (venous, 6.7%; arterial,
5.7%). Between diagnosis and enrollment, 207 patients (8.3%)
experienced a thrombotic event (venous, 5.2%; arterial, 3.5%). Of
the patients who experienced thrombotic events before PV diag-
nosis, 35 (11.8%) had a subsequent thrombotic event after PV
diagnosis. The exposure-adjusted thrombotic event rate between
diagnosis and enrollment was 1.55 per 100 patient-years. Among
patients who did not have a history of thrombotic events at time of
diagnosis, 7.0% had a thrombotic event after diagnosis.
Concomitant Medications
The 3 most common categories of concomitant medications were
statins (26.3%), selective b-blocking agents (18.9%), and
angiotensin-converting enzyme inhibitors (16.6%). Aspirin use was
reported in 62.9% of patients.
Health Care Resource Utilization
There were 667 patients (26.6%) who reported at least one
hospital, urgent care, emergency room, or outpatient visit within the
Table 1 Demographics and PV Disease Characteristics at
Enrollment for 2510 Patients
Characteristic Value
Age (y)
Mean (SD) 66.3 (12.3)
Median (range) 67.0 (22.0-95.0)
Male sex 1360 (54.2)
BMI (kg/m2) (n [ 2502)
Mean (SD) 28.7 (5.8)
Median (range) 28.0 (13.7-56.6)
Smoking
Ever smoked 1208 (48.1)
Smoking at baseline 279 (11.1)
Race
White 2237 (89.1)
Black or African American 143 (5.7)
Asian 37 (1.5)
Other 19 (0.8)
No information/missing 74 (2.9)
Ethnicity
Non-Hispanic/Latino 2293 (91.4)
Hispanic/Latino 98 (3.9)
No information/missing 119 (4.7)
Time from PV diagnosis to enrollment (y)
(n ¼ 2485), median (range)
4.0 (0-56.3)
Spleen Palpation
Spleen palpation performed 1601 (63.8)
Patients with palpable spleen 282 (11.2)
PV Risk
Low 570 (22.7)
Higha 1940 (77.3)
History of thrombosis (venous or arterial) 500 (19.9)
Positive family history of PV 132 (5.3)
Data are presented as n (%) unless otherwise indicated. Sample size is 2510 unless otherwise
indicated.
Abbreviations: BMI ¼ body mass index; PV ¼ polycythemia vera.
aAged  60 years and/or history of thrombotic events.
Figure 2 Duration of Disease at Enrollment. *Excluding 25
Patients With Missing Diagnosis Date
<1 y
1–<5 y
5–<10 y
10–<15 y
≥15 y
Missing
Evaluated,* n        2485
Median (range), y      4.0 (0–56.3)
21.7%
35.4%
23.4%
11.0%
7.5%
1.0%
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6 months before enrollment. Most of these patients (82.6%) re-
ported having outpatient medical care visits. PV was a causal factor
for 39.9% of all hospital, urgent care, emergency room, and
outpatient visits.
Discussion
The REVEAL study is the ﬁrst large, prospective observational
study to examine the contemporary demographics, burden of dis-
ease, clinical management, PROs, and health care resource utiliza-
tion among US patients with PV. Enrolled patients represent a
broad, real-world segment of the PV population who are actively
being managed at community or academic centers. In this analysis
of clinical and disease characteristics at time of enrollment to
REVEAL, patients were mostly male (54.2%) and had a mean (SD)
age of 66.3 (12.3) years, with a median (range) PV disease duration
of 4.0 (0-56.3) years. In the Cytoreductive Therapy in Poly-
cythemia Vera (CYTO-PV) study, which had similar eligibility
criteria, 62.2% were male, mean (SD) age at recruitment/enroll-
ment was 65 (12) years, and mean (SD) time from diagnosis to
enrollment was 4.3 (5.4) years.26 Baseline data reported from the
1638 patients included in the database collected during the obser-
vational study of the European Collaboration on Low-Dose Aspirin
in Polycythemia Vera (ECLAP) project revealed that 57.5% were
male, mean (SD) age at recruitment/enrollment was 60 (13) years,
and mean (SD) time from diagnosis to enrollment was 5.0 (5.0)
years.27 Demographic statistics from REVEAL are similar to those
reported by other highly regarded studies.
Bone marrow biopsy and JAK2 mutation testing are important to
differentiate between a PV diagnosis and myeloﬁbrosis or essential
thrombocythemia; conﬁrmation of diagnosis by bone marrow bi-
opsy may affect treatment selection and potentially outcomes. At
the time of diagnosis, it was reported that < 25% of patients un-
derwent bone marrow biopsy/aspiration, and < 50% underwent
JAK2 mutation testing. Of the patients who did undergo JAK2
mutation testing, approximately 96% had a JAK2 V617F mutation,
and approximately 1% had other JAK2 mutations (eg, exon 12).
Because the majority of patients did not have JAK2 mutation testing
to verify diagnosis, it is possible that some do not truly have PV.
Importantly, JAK2 mutation testing is increasing over time. Ac-
cording to data reported in this study, of the patients diagnosed in
the 3-year intervals of 2005-2007, 2008-2010, 2011-2013, and
2014-2016, 38%, 57%, 57%, and 61% underwent JAK2 mutation
testing, respectively. However, even when taking into consideration
that the JAK2 mutation was discovered in 2005 and the time
needed for this mutation testing to become widely available to all
practice settings, the rates of JAK2 mutation testing reported in this
study seem low. Similarly, the percentage of patients who reportedly
underwent bone marrow biopsy and/or erythropoietin testing seems
low. These low rates may be related to the various ways in which
these data are acquired, recorded, and abstracted from electronic
medical records.28
Regarding the management of patients with low-risk disease, in
line with National Comprehensive Cancer Network clinical practice
guidelines,29 the majority (54.6%) of patients were managed with
phlebotomy with or without aspirin. However, > 40% of low-risk
Table 3 Polycythemia VeraeRelated Laboratory Values at
Enrollment in 2510 Patients
Characteristic Value
Hemoglobin
No. evaluated 2241
Mean (SD; range) (g/dL) 14.5 (1.9; 8.2-22.1)
Elevateda 118 (5.3%)
Hematocrit
No. evaluated 2242
Mean (SD; range) (%) 45 (5.7; 25-70)
> 45% 1070 (47.7%)
Platelet Count
No. evaluated 2212
Mean (SD; range) (109/L) 367.5 (186.4; 15.0-1542.0)
> 400  109/L 792 (35.8%)
Leukocyte Count
No. evaluated 2219
Mean (SD; range) (109/L) 10.4 (7.2; 0.70-151.3)
> 10  109/L 821 (37.0%)
aDeﬁned as > 18.5 g/dL for men and > 16.5 g/dL for women.
Table 2 Abnormal Laboratory Tests and Polycythemia Verae
Related Signs and Symptoms at Time of Diagnosis in
2510 Patients
Characteristic Value
Abnormal Laboratory Testa
Hemoglobin 1482 (59.0)
Hematocrit 1443 (57.5)
Platelet count 720 (28.7)
White blood cell count 499 (19.9)
Erythropoietin level 505 (20.1)
Red blood cell count 454 (18.1)
Red cell mass 105 (4.2)
Serum LDH 88 (3.5)
EEC growth 8 (0.3)
Palpable splenomegaly 175 (7.0)
Mutational Test 1236 (49.2)
JAK2 V617F, n/N (%)b 1184/1236 (95.8)
JAK2 other, n/N (%)b 10/1236 (0.8)
Missing, n/N (%)b 42/1236 (3.4)
Bone marrow test 612 (24.4)
Symptoms (Documented by
Physician)
Tiredness 552 (22.0)
Itching 349 (13.9)
Muscle aches and/or bone pain 220 (8.8)
Difﬁculty sleeping 195 (7.8)
Data are presented as n (%) unless otherwise indicated.
Abbreviations: EEC ¼ endogenous erythroid colony; JAK2 ¼ Janus kinase 2; LDH ¼ lactate
dehydrogenase.
aAs reported by survey respondents; deﬁnitions of “abnormal” were not available. A patient
could be counted in > 1 category.
bDenominator of 1236 is number of patients who had mutational analysis data from peripheral
blood test or other test.
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patients received hydroxyurea or some other cytoreductive therapy
with or without aspirin. Conversely, approximately one third of
high-risk patients were managed without cytoreductive medications
with or without aspirin. These data suggest variance from guideline-
deﬁned risk-adapted treatment of PV, which was published after
many of these patients were diagnosed and enrolled.30 It is
important to note that treatment with aspirin was reported in
62.9% of patients, but it is likely that, in some patients, over-the-
counter use of aspirin was not reported or recorded.
With respect to thrombotic events, 11.9% of patients in
REVEAL experienced thrombotic events before PV diagnosis
(venous, 6.7%; arterial, 5.7%), and 8.3% experienced a thrombotic
event between diagnosis and enrollment. In comparison, 14% of
patients with PV had thrombotic events before diagnosis, and 19%
had a thrombotic event during a 20-year follow-up in a retrospective
study of 1213 patients in Italian hematology institutions conducted
in 1995.18
Conclusion
As the ﬁrst prospective observational study of its size to assess US
patients with PV, REVEAL is expected to provide information that
will improve our understanding of the demographics, diagnosis,
management, and outcomes of these patients. This analysis de-
scribes patient demographics as well as clinical and disease charac-
teristics at the time of diagnosis and around the time of enrollment.
REVEAL baseline data indicated that the JAK2 V617F mutation
rate among patients who underwent molecular testing was consis-
tent with previous reports.4,31 However, the reported percentage of
patients who underwent testing was much lower than expected,
which could be related to the challenges of capturing retrospective
data from medical records. Many patients had poorly controlled
hematocrit, platelet, and leukocyte counts at enrollment, with
elevated hematocrit values observed in nearly half of all evaluated
patients. Additional prospective data from REVEAL (eg, treatment
patterns, PROs, and cardiovascular risk assessments) will be
Figure 3 PV-Related Treatment at Enrollment. For “Other Agents,” Patients Could Be Counted in More Than One Category; Treatment
Included Ruxolitinib (3.8%), Anagrelide (2.0%), Interferons (1.4%), and Other (1.2%). Treatment Was Unknown for 2 Patients
33.6%
29.0%
23.7%
8.2%
0.1%
Phlebotomy + 
hydroxyurea
Other agents
Watchful waiting ± aspirin
Phlebotomy ±
aspirin
Hydroxyurea ± aspirin
Missing
PV-Related Treatment at Enrollment in Low- and High-Risk Patients 
Treatment, n (%)
Low risk
(n=570)
High-risk patients
Age 
≥60 y
(n=1440)
   TE 
History 
(n=125)
Age ≥60 y + 
TE history 
(n=375)
All 
patients
(N=1940)
Phlebotomy ±
aspirin 311 (54.6) 402 (27.9) 48 (38.4) 82 (21.9) 532 (27.4)
Hydroxyurea ±
aspirin 103 (18.1) 464 (32.2) 35 (28.0) 125 (33.3) 624 (32.2)
Phlebotomy + 
hydroxyurea 90 (15.8) 388 (26.9) 20 (16.0) 96 (25.6) 504 (26.0)
Other agents 38 (6.7) 106 (7.4) 16 (12.8) 46 (12.3) 168 (8.7)
Watchful waiting ±
aspirin 28 (4.9) 78 (5.4) 6 (4.8) 26 (6.9) 110 (5.7)
Missing 0 2 (0.1) 0 0 0
PV, polycythemia vera; TE, thrombotic event.
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important for understanding how the disease progresses and how
management changes with time.
Clinical Practice Points
 PV is a Philadelphia chromosomeenegative myeloproliferative
neoplasm that can be diagnosed on the basis of absolute eryth-
rocytosis (hemoglobin > 16.5 g/dL in men, hemoglobin
> 16 g/dL in women), bone marrow biopsy, and the presence of
JAK2 V617F or JAK2 exon 12 mutation. According to World
Health Organization PV diagnostic criteria, bone marrow biopsy
may not be required in cases of sustained absolute erythrocytosis
(hemoglobin > 18.5 g/dL in men or > 16.5 g/dL in women) in
the presence of one of the JAK2 mutations and a subnormal
serum erythropoietin level.
 In this observational study, the retrospective review and
abstraction of data from electronic medical records limits
deﬁnitive conclusions regarding diagnostic approach.
 The primary goal of treatment is prevention of arterial and venous
thrombotic events. In general, risk-adapted treatment consists of
phlebotomy and aspirin in low-risk patients (< 60 years and no
history of thrombosis). In high-risk patients ( 60 years and/or
with a history of thrombosis), cytoreductive therapy is usually
added to phlebotomy and aspirin. Data collected from REVEAL
suggest variance from guideline-deﬁned risk-adapted treatment
of PV.
 During treatment, patients with PV should be monitored every 3
to 6 months for new thrombohemorrhagic events, increased
need/intolerance of phlebotomy, progressive/symptomatic
splenomegaly, symptomatic thrombocytosis, progressive leuko-
cytosis, and progressive disease-related symptoms. This close
clinical surveillance is necessary to determine whether a cytore-
ductive therapy is indicated for low-risk patients or whether a
different medication should be selected for high-risk patients.
 Baseline characteristics of patients with PV enrolled in
REVEAL are similar to those reported by other highly regarded
studies.
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Supplemental Table 1 Education, Employment, Insurance,
and Residency Characteristics at
Enrollment for 2510 Patients
Characteristic N (%)
Highest Level of Education
Less than high school 114 (4.5)
High school graduate/equivalent 805 (32.1)
Some college 556 (22.2)
College degree 686 (27.3)
Graduate degree 332 (13.2)
Missing 17 (0.7)
Current Employment Statusa
Full-time employee 721 (28.7)
Part-time employee 119 (4.7)
Homemaker 89 (3.5)
Student 7 (0.3)
Retired 1282 (51.1)
Unable to work/disabled 110 (4.4)
Other 73 (2.9)
Unknown 107 (4.3)
Missing 2 (0.1)
Health Insuranceb
Medicare 1350 (53.8)
Preferred provider organization 629 (25.1)
Health maintenance organization 289 (11.5)
Medicaid 109 (4.3)
TRICARE 73 (2.9)
Self-insured 32 (1.3)
Veterans Affairs/Department of
Defense
24 (1.0)
Otherc 353 (14.1)
None 16 (0.6)
Patient Residency Setting
At home, living independently 2381 (94.9)
At home, living as dependent 93 (3.7)
Assisted living 20 (0.8)
Long-term care facility 3 (0.1)
Other 9 (0.4)
Missing 4 (0.2)
aFirst choice as listed in sequence of electronic data captured.
bPatients may have been included in more than one health insurance category.
cIncludes range of health insurance and prescription plans and may include some that are
reported within other categories.
REVEAL Preliminary Report
795.e1 - Clinical Lymphoma, Myeloma & Leukemia December 2018
Supplemental Table 2 Most Common Comorbid Conditions in
2510 Patients
Condition N (%)
Select Cardiovascular DiseaseeRelated Conditions
Hypertension 1772 (70.6)
Hyperlipidemia 763 (30.4)
Obesitya 440 (17.5)
Diabetes mellitus 395 (15.7)
History of Cancer in ‡ 1% of Patients
Skin 88 (3.5)
Nonmelanoma skin cancer 83 (3.3)
Prostate 73 (2.9)
Breast 48 (1.9)
Malignant melanoma 27 (1.1)
Colon 25 (1.0)
aPer discretion of managing physician.
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